Survival chance in papillary thyroid cancer in Hungary: individual survival probability estimation using the Markov method

Ésik, Olga; Tusnády, Gábor; Daubner, K; Németh, György; Füzy, M.; Szentirmay, Zoltán

doi:10.1016/s0167-8140(97)00098-4

Cited by 12 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of distant metastases in the initial work‐up and during follow‐up was highly associated with poor prognosis of PTC in our study and similar results had been reported in previous studies . Several studies have suggested that receiving 131 I therapy, especially right after detection of distant metastases, could improve the prognosis of patients with distant metastases .…”

Section: Discussionsupporting

confidence: 89%

The impact of locoregional recurrences and distant metastases on the survival of patients with papillary thyroid carcinoma

Chang

2014

Clinical Endocrinology

View full text Add to dashboard Cite

SummaryObjective Some patients with papillary thyroid carcinoma (PTC) would suffer from locoregional recurrences or distant metastases. This study was aimed to elucidate the impacts of locoregional recurrences and distant metastases on these patients' survival. Design Retrospective hospital-based cohort study. Population Data were collected from 1636 subjects with PTC at National Taiwan University Hospital between 1985 and 2007. Measurements Overall and disease-specific survival curves were estimated by the Kaplan-Meier method. Time-independent and time-dependent prognostic factors were included simultaneously in multivariate analyses using Cox models. Results Overall survival (OS) rates at 10-and 20-years were 90% and 76%, respectively. The 10-and 20-year disease-specific survival (DSS) rates were 95% and 90%, respectively. Our multivariate analyses identified that older age, distant metastases (hazard ratio, HR: 6Á69, 95% CI: 4Á40-10Á18), locoregional recurrences (HR: 1Á88, 95% CI: 1Á22-2Á89), lymph node metastases, massive extrathyroid extension, male gender and larger tumour size (>4 cm) were significantly associated with poorer OS. Older age, distant metastases (HR: 15Á03, 95% CI: 8Á31-27Á21), locoregional recurrences (HR: 3Á63, 95% CI: 2Á03-6Á51), massive extrathyroid extension, male gender and larger tumour size (>4 cm) were independently related to worse DSS. The performance of highdose 131 I ablation had a protective effect on OS and DSS. Conclusion The locoregional recurrences had a moderately harmful impact on OS and DSS, but age and distant metastases were the major decisive factors for OS and DSS. High-dose 131

show abstract

Section: Discussionsupporting

confidence: 89%

The impact of locoregional recurrences and distant metastases on the survival of patients with papillary thyroid carcinoma

Chang

2014

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Moreover, it requires accurate information for a large sample of patients with a long follow-up to achieve a statistical power sufficient to ensure conclusive results [27]. Screening of literature revealed very few applications of the Markov model in cancer epidemiology, particularly for studying the prognostic impact of intermediate events, such as recurrence, on metastatic progression or death [39][40][41]. None of these articles were published in epidemiology journals, and none dealt with digestive cancers.…”

Section: Discussionmentioning

confidence: 99%

Modeling recurrence in colorectal cancer

Dancourt

Quantin

Abrahamowicz

et al. 2004

Journal of Clinical Epidemiology

View full text Add to dashboard Cite

“…The only meta-analysis 9 published to date summarized the results of 10 heterogeneous case series and cohort studies 10,11,12,13,14,15,16,17,18,19 involving more than 4000 patients with unknown baseline risk of recurrence. These studies showed a significant 27% risk reduction of combined mortality and disease recurrence rate in patients treated with thyrotropin suppression (eTable 1 in the Supplement).…”

Section: Discussionmentioning

confidence: 99%

“…Clinical data evaluating the relationship between thyrotropin suppression and long-term DTC outcomes such as survival are equivocal 9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29 (eTable 1 in the Supplement). Several studies have uniformly documented that thyrotropin suppression is not necessary in patients with low-risk DTC.…”

Section: Introductionmentioning

confidence: 99%

Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer

et al. 2019

View full text Add to dashboard Cite

Key Points Question Is thyrotropin suppression associated with better outcomes in patients with intermediate- and high-risk differentiated thyroid cancer? Findings In this cohort study including 867 patients with intermediate- and high-risk differentiated thyroid cancer followed up for a mean (SD) of 7.2 (5.8) years, thyrotropin suppression was not associated with improved progression-free survival or overall survival. Meaning Patients with intermediate- and high-risk differentiated thyroid cancer might not benefit from thyrotropin suppression.

show abstract

Survival chance in papillary thyroid cancer in Hungary: individual survival probability estimation using the Markov method

Cited by 12 publications

References 25 publications

The impact of locoregional recurrences and distant metastases on the survival of patients with papillary thyroid carcinoma

The impact of locoregional recurrences and distant metastases on the survival of patients with papillary thyroid carcinoma

Modeling recurrence in colorectal cancer

Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer

Contact Info

Product

Resources

About